TransCode Therapeutics develops TTX-MC138, a targeted therapy that inhibits microRNA-10b, a master regulator of metastatic tumor cell viability, to treat metastatic cancer across various types. The company utilizes a tunable iron oxide nanoparticle delivery platform to effectively transport therapeutic oligonucleotides to tumor sites, addressing the challenge of treating cancer that has spread beyond the primary tumor.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic cancer, where cancer cells spread from the primary tumor to distant sites, remains a significant challenge in oncology. Traditional cancer treatments often focus on the primary tumor, overlooking the unique genetic makeup and behavior of metastatic tumor cells. This oversight limits the effectiveness of therapies in eradicating the disease and preventing recurrence.
Solution
TransCode Therapeutics is developing TTX-MC138, a targeted therapy designed to inhibit microRNA-10b, a master regulator of metastatic tumor cell viability. The therapy utilizes a tunable iron oxide nanoparticle delivery platform (TTX) to effectively transport therapeutic oligonucleotides to tumor sites and metastases. By specifically targeting and eradicating metastatic tumor cells, TTX-MC138 aims to induce regression of disease and prevent recurrence. Pre-clinical studies have demonstrated durable regression of established metastases in murine models of metastatic breast cancer and pancreatic cancer following treatment with TTX-MC138.
Target Audience
The primary target audience includes cancer patients with metastatic disease across various cancer types, as well as oncologists and researchers focused on developing targeted therapies for metastatic cancer.
Features
- Targets microRNA-10b, a master regulator of metastatic tumor cell viability
- Utilizes a tunable iron oxide nanoparticle delivery platform (TTX) for targeted delivery of therapeutics to tumors and metastases
- Demonstrated durable regression of established metastases in murine models of metastatic breast cancer and pancreatic cancer
- Designed to specifically eradicate metastatic tumor cells, which have evolved from the primary tumor
- Has potential applicability across various cancer types, including breast, pancreatic, ovarian, and colon cancer, and glioblastomas
- Hormone receptor independent, potentially treating metastatic breast cancer regardless of type (ER+/-, PR+/, HER2+/-)